Q Bio Med Inc. QBIO
We take great care to ensure that the data presented and summarized in this overview for Q BioMed Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in QBIO
Top Purchases
Top Sells
About QBIO
Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride SR89 and Metastron, a radiopharmaceutical therapeutic for the treatment of metastatic bone cancer pain. It is also developing Man-01, a pre-clinical lead candidate for the treatment of primary open angle glaucoma; QBM-001 for rare pediatric non-verbal autism spectrum disorder; and Uttroside-B for liver cancer. Q BioMed Inc. has a partnership with Mannin Research Inc. for the development of therapeutics to treat acute respiratory distress syndrome, glaucoma, kidney diseases, and others. The company was formerly known as ISMO Tech Solutions, Inc. and changed its name to Q BioMed Inc. in July 2015. Q BioMed Inc. was incorporated in 2013 and is based in New York, New York.
Insider Transactions at QBIO
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 26
2022
|
Denis Corin Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
200,000
+7.04%
|
$4,000,000,000
$20000.0 P/Share
|
|
May 26
2022
|
William S Rosenstadt Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
250,000
+21.24%
|
$6,250,000,000
$25000.0 P/Share
|
|
Feb 01
2021
|
William S Rosenstadt Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
35,000
+5.08%
|
-
|